|Bid||11.05 x 900|
|Ask||15.00 x 1300|
|Day's Range||12.95 - 14.07|
|52 Week Range||10.62 - 19.84|
|Beta (5Y Monthly)||N/A|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||25.50|
Klausner, who headed the National Cancer Institute for many years, is a well-respected investor in biotech companies and has reportedly been tagged as CEO of Altos Labs, an aging-focused startup setting up shop in Redwood City.
Insiders who acquired US$300k worth of Lyell Immunopharma, Inc.'s ( NASDAQ:LYEL ) stock at an average price of US$17.00...
SOUTH SAN FRANCISCO, Calif., Sept. 08, 2021 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (Lyell), (Nasdaq: LYEL), a T cell reprogramming company dedicated to the mastery of T cells to cure patients with solid tumors, today announced that members of its senior management team will participate in a virtual fireside chat at the Morgan Stanley 19th Annual Global Healthcare Conference on Wednesday, September 15, at 2:00 PM ET. A live webcast of the fireside chat can be accessed through the investor r